Combining a broad-spectrum tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma:

https://www.kcuk.org.uk/nivolumabsitravatinib-combo-impresses-in-rcc/